Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0038362 (stomatitis)
 8,852 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The glucagonoma syndrome is characterized by dermatitis, stomatitis, elevated serum glucagon levels, abnormal glucose tolerance, weight loss, and anemia--all in association with a glucagon-secreting alpha-cell tumor of the pancreas. A review of 21 cases showed strikingly similar features. A generalized, symmetrical dermatitis initially appeared to be asteatotic or eczematous over the perineum, buttocks, and lower extremities. Gradually, a more characteristic migratory necrolytic erythema with transient bulla formation and erosions developed in intertriginous and dependent areas. Histologically, the most specific features included necrolysis of the upper epidermis, with liquefaction necrosis of the granular cell layer and subcorneal clefting or blister formation. The dermatologist is often first to examine such patients; early recognition of this syndrome with prompt surgical removal of the primary pancreatic lesion may afford cure of the neoplasm.
 ...
PMID:Glucagonoma syndrome. Report of two cases and literature review. 19 36

A hitherto undescribed clinical and histologic entity occurring in the palate of 13 denture-wearing patients is described. Clinically it is characterized by the presence of small yellowish areas in the hard palate, which on pressure yield a whitish creamy material through multiple openings. The surrounding mucosa may exhibit various degrees of erythema. The histologic changes are characterized by the presence of intramucosal fistulae lined with unkeratinized squamous epithelium. The content of the fistulae, which corresponds to the creamy material expelled, consists of desquamated epithelial cells. These changes have mostly been noticed in elderly females, all wearing maxillary dentures for many years. This entity is considered a type of denture stomatitis characterized by intramucosal proliferation of epithelium, possibly because of long-standing chronic irritation from dentures. The origin of the intramucosal fistulae is unknown. The fistulae are believed to originate either from the ductus of the minor salivary glands or from the surface epithelium of the palate.
 ...
PMID:Denture stomatitis with multiple intramucosal fistulae. 28 77

It was the purpose of the study to test the efficiency of dextranase, mutanase, and protease in removing denture plaque. The study group comprised 100 denture-wearers with denture stomatitis. The enzymes were dispensed as dissolvent tablets either in pure or in mixed preparations. Placebo tablets and Steradent, a commercial denture cleanser, were used as control tablets. The following parameters were studied: the amount of denture plaque, the degree of palatal erythema, and the concentration of yeast cells and inflammatory cells in mucosal and denture smears. The study was designed and carried out as a double-blind study. The dissolvent tablets containing the enzymes in mixed preparations were more effective than the tablets containing the pure enzymes, the placebo tablets, or the Steradent tablets. The beneficial effect of the mixed enzyme preparations included a significant reduction of the amount of denture plaque and an improvement of the clinical condition of the palatal mucosa.
 ...
PMID:Enzymes as denture cleansers. 32 51

A 66-year-old male patient with non-insulin-dependent diabetes of probably 20 years' duration presented with necrolytic migratory erythema, stomatitis, anemia and weight loss. Plasma-glucagon concentration measured with Unger's antibody 30-K was 8500 pg/ml, representing a hundredfold elevation. Two thirds consisted of high molecular glucagon fractions (10 000--40 000 Dalton). This may be an important index for detection of glucagonoma with endocrine activity. After excision of the glucagonoma the clinical syndrome was reversed and the patient recovered completely. Histological and histochemical investigation confirmed that the tumor was a glucagonoma. Despite complete removal of the tumor and a normal plasma glucagon concentration, the diabetes remained unchanged. Excessive hyperglucagonemia does not appear to play a primary role in the pathogenesis of this patient's diabetes.
 ...
PMID:[The course of diabetes and clinical findings in glucagonoma]. 52 94

Sixty-one patients with advanced disseminated cancer were given progressively increasing doses of pyrazofurin to evaluate toxicity patterns and to establish the dosage that produces maximum therapeutic effect with clinically tolerable toxicity. The drug was given by intravenous injection over 5-day courses repeated every 2--3 weeks. Toxic reactions included stomatitis, myelosuppression, skin rash, erythema, proctitis, and occasional nausea and vomiting. Stomatitis was the dose-limiting toxicity and it occurred in 32 patients. Myelosuppression was mild to moderate. Of 75 evaluable courses for marrow toxicity, leukopenia occurred in 14 and thrombocytopenia in 28. Thrombocytopenia was apparently dose-independet. Marrow recovery was complete by day 21 of therapy. Twelve patients developed mild or severe cutaneous toxicity depending on dose. When mild, the skin changes consisted of self-limited erythema or rash, and when severe, bullous lesions and skin ulcers were also observed. Proctitis occurred in six patients and was associated with severe stomatitis. Nausea and vomiting were occasional and mild. There was no evidence of liver or renal toxicity. All toxic manifestations other than marrow toxicity were dose-related. No responses were observed. A reasonable dose schedule is 45 mg/m2/day X 5 repeated every 3 weeks. We recommend that Phase II studies be pursued particularly in diseases that have been shown to be sensitive to the drug.
 ...
PMID:A phase I study of pyrazofurin. 58 56

The purpose of this study was to assess whether frequent exposure to sucrose would aggravate or initiate a palatal candidosis in denture wearers. Eight subjects with generalized simple or granular inflammation in the palate (inflammation group) and six with clinically healthy palatal mucosa (control group) carried out 1-min mouthrinses with 10 ml of a 25% sucrose solution four times daily for 15 d. In the inflammation group an aggravated palatal erythema was seen in two subjects after 7 d, and in another subject after 15 d. Among the controls a generalized simple inflammation had developed in the palate of one subject after 7 d, and in another one after 15 d. An increased number of yeast colonies on palatal and denture agar models and/or hyphae on palatal and denture smears was found in all subjects with clinical signs of aggravated or initiated denture stomatitis.
 ...
PMID:Initiation and aggravation of denture stomatitis by sucrose rinses. 106 49

Thirty patients with Behcet's disease were treated with immunosuppressive drugs, 25 with Imuran, 5 with Leukerin and 2 with both these drugs. Daily administration of 50-75 mg of Imuran over a period of 1 year alleviated the ocular symptoms in 16% of patients, was slightly effective in 20%, and ineffective in 64%. Imuran therapy was also seen to alleviate the extraocular pathology, such as stomatitis, erythema, and arthralgia. Leukerin proved difficult to prescribe over a long period because of severe side effects.
 ...
PMID:Immunosuppressive treatment of Behcet's disease. 125 Feb 36

Patients with severe immunosuppression as a consequence of infection by human immunodeficiency virus (HIV) are at risk for a number of severe periodontal diseases. HIV-associated gingivitis and HIV-associated periodontitis (HIV-P) are seen exclusively in HIV-infected persons. In some cases HIV-P may extend into adjacent soft tissue and bone, resulting in necrotizing stomatitis of periodontal origin. In addition, acute necrotizing ulcerative gingivitis has also been reported to have an increased prevalence in HIV-infected patients. The clinical and microbiologic features of HIV-associated gingivitis and HIV-P suggest that these diseases are early and later stages of the same lesion, that results in severe gingival erythema, extensive soft tissue necrosis, and destruction of alveolar bone. Although acute necrotizing gingivitis and the initial stages of HIV-P share a number of clinical signs current evidence indicates that they are distinct pathologic processes. Treatment of these lesions requires debridement, local antimicrobial therapy, immediate follow-up care, and long-term maintenance. In addition, patients with systemic involvement or extensive and rapidly progressing lesions may require systemic antibiotics appropriate to the organisms that dominate the lesion.
 ...
PMID:Periodontal disease associated with HIV infection. 153 35

A 49-year-old woman suffered from recurrent episodes of necrolytic migratory erythema over the lower legs, lower abdomen, and buttocks for more than two years. Stomatitis, glossitis and vaginitis were the accompanying symptoms and signs during each episode. The result of skin biopsy revealed superficial necrosis in the upper half of the epidermis. Laboratory examinations revealed mild glucose intolerance and hypoaminoacidemia. Fasting plasma glucagon level measured by radioimmunoassay was 890 pg/mL. Oral glucose loading test showed a paradoxical increase in plasma glucagon level up to 1,500 pg/mL. Abdominal echo, computerized axial tomography, and celiac angiography demonstrated a hypervascular tumor, 4 cm in diameters, located at the pancreatic head. Glucagonoma syndrome was confirmed and diagnosed. The patient underwent surgical resection of the tumor mass. Necrolytic migratory erythema disappeared thereafter, and the plasma glucagon level declined to 120 pg/mL. Histologically, the tumor revealed an islet cell carcinoma composed of moderately uniform cells with a few mitosis, arranged in cords and nests. Abundant characteristic secretory granules of the pancreatic A cell were found within the tumor cells by electron microscopic examination.
 ...
PMID:[Necrolytic migratory erythema as the first manifestation of glucagonoma]. 168 96

We have studied whether mouth-swishing with sucralfate, a well-known gastric mucosal protective agent, may be used as prophylaxis against chemotherapy-induced stomatitis. Using radioactively labelled sucralfate we found that 20-30% was still bound to the oral mucosal lining 2 1/2 h after mouth-swishing. Forty patients receiving cisplatin and continuous infusion with 5-fluorouracil (5-FU) for 5 days entered a double-blind placebo-controlled cross-over study. Among 23 evaluable patients a significant reduction (p = 0.04) in an objective score of edema, erythema, erosion and ulcerations was seen during treatment with sucralfate. Patient preference favored sucralfate, but this preference failed to reach statistical significance (p = 0.06). Seven patients were inevaluable for reasons not associated with the study treatment. However, ten patients did not complete the study since the swishing procedure aggravated chemotherapy-induced nausea. An equal rate of non-compliance was seen with sucralfate and placebo. To overcome this problem, the oral medication should have a neutral taste, the solution should not be swallowed after the swishing, which should not be started until the nausea had ceased.
 ...
PMID:Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. A randomized, double-blind cross-over study. 169 28


1 2 3 4 5 6 7 8 9 Next >>